Telix Pharmaceuticals Ltd
TLX Nasdaq
SEC CIK 2007191
Follow Telix Pharmaceuticals
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $803.8M | −$7.1M |
| FY24 | $516.6M | $33.7M |
| FY23 | $333M | $4.2M |
| FY22 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 53.1% | 3.7% | −0.9% |
| FY24 | 65.1% | 10.7% | 6.5% |
| FY23 | 62.9% | 3.3% | 1.3% |
| FY22 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$43M |
| FY24 | $18.4M |
| FY23 | $8M |
| FY22 | - |
- Telix Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Telix Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −0.9% | −30.6% |
| FY24 | 6.5% | −47% |
| FY23 | 1.3% | −58% |
| FY22 | - | −80.4% |